Formation of the Scandinavian Obesity Surgery Registry, SOReg

Hedenbro, Jan; Näslund, Erik; Boman, Lars; Lundegårdh, Göran; Bylund, Amy; Ekelund, Mikael; Laurenius, Anna; Möller, Peter; Olbers, Torsten; Sundbom, Magnus; Ottosson, Johan; Näslund, Ingmar

doi:10.1007/s11695-015-1619-5

Cited by 131 publications

(113 citation statements)

References 20 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Moreover, SOReg-data has been found to be reliable with a very low risk for incorrect values, when systematically validated, or continuously searched for non-logic or unlikely values 7 . To counter the 45% follow-up rate in SOReg a cross-reference was done with the PDR allowing 100% follow-up of medically treated comorbid diseases.…”

Section: Discussionmentioning

confidence: 99%

“…1.2% leaks) and mortality are low (0.04%), the latter validated with the Swedish Population Register. Regular audits are performed by randomly comparing data in SOReg with patient charts at the surgical centers, demonstrating a high validity with less than 2% incorrect values 7 . Furthermore, by crosslinkage with the national Prescribed Drug Registry (PDR) a 100% follow-up of the occurrence of comorbid disease (defined as medical treatment) can be achieved.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Substantial Decrease in Comorbidity 5 Years After Gastric Bypass

et al. 2017

View full text Add to dashboard Cite

Objective: To evaluate effect on comorbid disease and weight loss five years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a large nationwide cohort. Summary Background Data:The number patients having surgical procedures to treat obesity and obesity-related disease are increasing. Yet, population-based, long-term outcome studies are few. Results: BMI decreased from 42.8 ±5.5 to 31.2 ±5.5 kg/m 2 at five years, corresponding to 27.7%-reduction in total body weight. Prevalence of T2DM was reduced (15.5% to 5.9%), hypertension (29.7% to 19.5%), dyslipidemia (14.0% to 6.8%) and sleep apnea (9.6% to 2.6%). Greater weight loss was a positive, while increasing age or BMI at baseline, were negative prognostic factors for remission. The use of anti-depressants increased (24.1% to 27.5%). Laboratory status was improved, e.g. fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4 mmol/mol and 41.8 to 37.7%, respectively. Conclusions:In this nationwide study, gastric bypass resulted in large improvements in obesity-related comorbid disease and sustained weight loss over a five-year period. The increased use of anti-depressants warrants further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Substantial Decrease in Comorbidity 5 Years After Gastric Bypass

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The SOReg was initiated in 2004 and includes all centers performing obesity surgery in Sweden since 2013 [16]. The register contains preoperative data and information on surgical procedure as well as short-and long-term outcomes.…”

Section: The Scandinavian Obesity Surgery Registrymentioning

confidence: 99%

Validation of Obesity Surgery Data in the Swedish National Patient Registry and Scandinavian Obesity Registry (SOReg)

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Data are collected prospectively at the time of surgery, at 6 weeks and at 1, 2 and 5 years postoperatively. The registry has been described elsewhere [12], and in the operative module, the length and number of cartridges used to the construct the pouch size are entered, as a non-compulsory variable. The SOReg database has been validated, and more than 98 % of entered data were correct [11].…”

Section: Introductionmentioning

confidence: 99%